PGR and breast cancer: Since the prognosis of breast cancer differs according to the molecular subtype, guidelines recommend core biopsy for immunohistochemical assessment of ER, PgR, and HER2 status to classify the molecular subtype of breast cancer during initial diagnosis [6,7,8].